Standout Papers

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study 2016 2026 2019 2022 1.1k
  1. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study (2016)
    Rita Nanda, Laura Q.M. Chow et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 31 from Science/Nature 75 standout
Sub-graph 1 of 23

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Physiology and diseases of tissue-resident macrophages
2023 StandoutNature
2 intermediate papers

Works of Rita Nanda being referenced

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
2016 Standout

Author Peers

Author Last Decade Papers Cites
Rita Nanda 1163 387 292 494 22 1.4k
Vidya Maiya 1366 471 511 423 13 1.6k
Stephen J. Luen 939 339 301 440 32 1.3k
Shilpen Patel 944 332 405 282 19 1.2k
Sheela Tejwani 1081 520 454 616 23 1.6k
Yang Zhao 933 202 214 718 34 1.6k
Mehrdad Rakaee 940 558 363 530 39 1.6k
Danielle Carpenter 1185 219 208 863 38 2.0k
Song‐Yang Wu 656 253 366 563 23 1.3k
Vaibhav G. Patel 827 551 340 318 46 1.7k
Shu Zhao 766 323 398 235 42 1.3k

All Works

Loading papers...

Rankless by CCL
2026